Inhibition of tissue-factor-mediated thrombin generation by simvastatin

Atherosclerosis

Volumn 149, Issue 1, 2000, Pages 111-116

  Ferro, Domenico ^a   Basili, Stefania ^a   Alessandri, Cesare ^a   Cara, Doloretta ^a   Violi, Francesco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Monocyte tissue factor expression; Prothrombin fragment F1 + 2; Simvastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPOLYSACCHARIDE; PROTHROMBIN; SIMVASTATIN; THROMBIN; THROMBOPLASTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; INHIBITION KINETICS; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MONOCYTES; PROTHROMBIN; REFERENCE VALUES; SIMVASTATIN; STATISTICS, NONPARAMETRIC; THROMBOPLASTIN;

EID: 0033995229     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00291-9     Document Type: Article

References (22)

1. Pekkanen J., Linn S., Heiss G. et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 322:1990;1700-1807.
2. Carlson L.A., Danielson D., Ekberg I., Klintemar B., Rosenhamer G. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis. 27:1977;81-86.
3. Frick M.H., Elo O., Happa K. et al. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipemia. N. Eng. J. Med. 377:1987;1237-1245.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
5. Sacks F.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335:1996;1001-1009.
6. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 333:1995;1301-1307.
7. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J. Am. Med. Assoc. 279:1998;1643-1650.
8. Effect of simvastatin on coronary atheroma: the Multicentre AntiAtheroma Study (MAAS). Lancet. 344:1994;633-638.
9. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
10. Alessandri C., Basili S., Maurelli M. et al. Relationship between prothrombin activation fragment F1+2 and serum cholesterol. Haemostasis. 26:1996;214-219.
11. Ferro D., Basili S., Alessandri C., Mantovani B., Cordova C., Violi F. Simvastatin reduces enhanced monocyte tissue factor expression in patients with type IIa hypercholesterolemia. Lancet. 350:1997;1222.
12. Saliola M, Lorenzet R, Ferro D, Basili S, Caroselli C, Di Santo A, Sallese M, Violi F. Enhanced expression of monocyte tissue factor in patients with liver cirrhosis, Gut 1998 (in press).
13. Corsini A., Mazzotti M., Raiteri M. et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis. 101:1993;117-125.
14. Tijburg P.N.M., Ryan S., Stern D.T. et al. Activation of the coagulation mechanism on tumor necrosis factor-stimulated cultured endothelial cells and their extracellular matrix. J. Biol. Chem. 266:1991;12067-12074.
15. Osnes L.T.N., Westvik A.B., Kierulf P. Procoagulant and fibrinolytic activities of cryopreserved human monocytes. Thromb. Res. 76:1994;373-383.
16. Violi F., Ferro D., Basili S. et al. Association between low-grade disseminated intravascular coagulation and endotoxemia in patients with liver cirrhosis. Gastroenterology. 109:1995;531-539.
17. Armitage P., Berry G. Statistical methods in medical research. 2nd ed:1990;Blackwell, Oxford.
18. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;265-272.
19. Fernández-Ortiz A., Badimón J.J., Falk E. et al. Characterization of relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J. Am. Coll. Cardiol. 23:1994;1562-1569.
20. Wilcox I.N., Smith K.M., Schwartz S.M., Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA. 86:1989;2839-2842.
21. Moreno P.R., Bernardi V.H., López-Cuéllar J. et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Circulation. 94:1996;3090-3097.
22. Ardissino D., Merlini P.A., Ariëns R., Coppola R., Bramucci E., Mannucci P.M. Tissue factor antigen and activity in human atherosclerotic plaques. Lancet. 349:1997;769-771.